BioCardia, Inc. (BCDA)

NASDAQ: BCDA · IEX Real-Time Price · USD
2.09
-0.05 (-2.34%)
At close: Oct 7, 2022 4:30 PM
2.16
+0.07 (3.35%)
After-hours: Oct 7, 2022 5:36 PM EDT
-2.34%
Market Cap 37.11M
Revenue (ttm) 1.93M
Net Income (ttm) -11.99M
Shares Out 17.76M
EPS (ttm) -0.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 49,855
Open 2.15
Previous Close 2.14
Day's Range 2.04 - 2.18
52-Week Range 1.10 - 3.09
Beta 1.23
Analysts Buy
Price Target 8.67 (+314.8%)
Earnings Date Nov 8, 2022

About BCDA

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatme... [Read more...]

Industry Biotechnology
CEO Peter Altman
Employees 28
Stock Exchange NASDAQ
Ticker Symbol BCDA
Full Company Profile

Financial Performance

In 2021, BioCardia's revenue was $1.02 million, an increase of 600.00% compared to the previous year's $145,000. Losses were -$12.62 million, -15.87% less than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for BCDA stock is "Buy." The 12-month stock price forecast is 8.67, which is an increase of 314.83% from the latest price.

Price Target
$8.67
(314.83% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting

Clinical Leadership and Management Call Scheduled for Wednesday, October 5, 2022, at 8:55am Eastern Time Clinical Leadership and Management Call Scheduled for Wednesday, October 5, 2022, at 8:55am Easte...

4 days ago - GlobeNewsWire

CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data to be Presented at Heart Failure Society of Am...

Clinical Leadership and Management Call to Follow Clinical Leadership and Management Call to Follow

3 weeks ago - GlobeNewsWire

BioCardia Announces Participation at H.C. Wainwright Global Investment Conference September 12-14, 2022 (HYBRID CONFE...

SUNNYVALE, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ, BCDA), today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Con...

4 weeks ago - GlobeNewsWire

BioCardia to Participate in Cantor Fitzgerald's Cell and Genetic Medicines Conference

SUNNYVALE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], today announced it will participate on a panel as a presenting company at Cantor Fitzgerald's Cell and Genetic Medi...

4 weeks ago - GlobeNewsWire

Has BioCardia (BCDA) Outpaced Other Medical Stocks This Year?

Here is how BioCardia, Inc. (BCDA) and Ensign Group (ENSG) have performed compared to their sector so far this year.

1 month ago - Zacks Investment Research

BioCardia Enters Agreement with BlueRock Therapeutics to Provide Enabling Catheter Biotherapeutic Delivery Product Ca...

SUNNYVALE, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], today announced that it has entered into an agreement with BlueRock Therapeutics LP for the delivery of BlueRock's c...

1 month ago - GlobeNewsWire

BioCardia, Inc. (BCDA) Reports Q2 Loss, Tops Revenue Estimates

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 50% and 412.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

BioCardia Reports Second Quarter 2022 Business Highlights And Financial Results

SUNNYVALE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, tod...

1 month ago - GlobeNewsWire

BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022

SUNNYVALE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, tod...

2 months ago - GlobeNewsWire

BioCardia Announces First Canadian Clinical Site for CardiAMP Cell Therapy Heart Failure Trial

SUNNYVALE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, to...

2 months ago - GlobeNewsWire

BioCardia to Participate in Upcoming Heart and Pulmonary Therapy Development Symposia

SUNNYVALE, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], Sunnyvale, Calif. – BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the t...

2 months ago - GlobeNewsWire

BioCardia Announces US Patent on Imaging System for Targeting Cardiac Therapies

SUNNYVALE, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, to...

3 months ago - GlobeNewsWire

BioCardia, Inc. (BCDA) Reports Q1 Loss, Lags Revenue Estimates

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -26.67% and 68.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

BioCardia Reports First Quarter 2022 Business Highlights and Financial Results

SUNNYVALE, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, tod...

4 months ago - GlobeNewsWire

BioCardia to Host Q1 2022 Financial Results and Corporate Update Conference Call on May 11, 2022

SUNNYVALE, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, toda...

5 months ago - GlobeNewsWire

BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study

BioCardia (BCDA) gets FDA approval to start a phase I/II study to evaluate its allogenic stem cell therapy candidate, BCDA-04, in patients with ARDS due to COVID-19.

5 months ago - Zacks Investment Research

FDA Approves BioCardia's Phase 1 Trial With Cell Therapy In COVID-19, Shares Jump

The FDA has signed off BioCardia Inc's (NASDAQ: BCDA) Investigational New Drug (IND) application for BCDA-04 to initiate Phase 1/2 trial in adult patients recovering from Acute Respiratory Distress Synd...

5 months ago - Benzinga

BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering...

Phase I/II trial initiation expected in 3Q 2022 Phase I/II trial initiation expected in 3Q 2022

5 months ago - GlobeNewsWire

BioCardia Reports 2021 Financial Results and Recent Business Highlights

SUNNYVALE, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t...

6 months ago - GlobeNewsWire

BioCardia to Host 2021 Financial Results and Corporate Update Conference Call on March 29, 2022

SUNNYVALE, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, to...

6 months ago - GlobeNewsWire

BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell ...

New Procedure Reimbursement Code Expected to Enhance Study Performance for Clinical Centers Participating in the CardiAMP Cell Therapy Heart Failure Trial and the CardiAMP Cell Therapy Chronic Myocardia...

6 months ago - GlobeNewsWire

BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Fai...

SUNNYVALE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t...

7 months ago - GlobeNewsWire

Safety Board Recommends BioCardia's Heart Failure Cell Therapy To Continue Unchanged

The independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for BioCardia Inc's (NASDAQ: BCDA) ongoing Phase 3 CardiAMP Cell Therapy Heart Failure Trial. The DSMB base...

7 months ago - Benzinga

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart...

SUNNYVALE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, to...

7 months ago - GlobeNewsWire